West Pharmaceutical Services, 530 Herman O. West Drive, Exton, Pennsylvania 19341.
KBI Biopharma, 2500 Central Avenue, Colorado 80301.
J Pharm Sci. 2020 May;109(5):1725-1735. doi: 10.1016/j.xphs.2020.01.026. Epub 2020 Feb 1.
Evaluating a particle profile for parenteral drug products is a well-known challenge due to inevitable variability of results with limited accuracy to actual particle levels present in the product, especially in the subvisible particulate (SbVP) range. It is important to understand the appropriate SbVP counting/characterization technology, methodology capability, and the particle source (intrinsic or extrinsic). Elastomeric closures are prevalent in many types of drug product container closure systems and are a known source of particle contribution. These components need to be considered when establishing a drug product particle profile. In this work, we describe available particle extraction methodology and its applicability in the analysis of elastomeric closure components using multiple detection technologies. Optimum sample preparation and analytical techniques were established to evaluate submicron particle and SbVP loads from elastomeric closure components. In addition, the impact of stopper siliconization and polysorbate 80 interaction on the degree of SbVPs in the final drug product was assessed.
评估注射用药物产品的颗粒分布是一项众所周知的挑战,因为其结果不可避免地存在变异性,而且对产品中实际颗粒水平的准确性有限,尤其是在亚可见颗粒(SbVP)范围内。了解适当的 SbVP 计数/表征技术、方法能力以及颗粒来源(内在或外在)非常重要。弹性密封件在许多类型的药物产品容器密封系统中很常见,是颗粒贡献的已知来源。在建立药物产品颗粒分布时需要考虑这些组件。在这项工作中,我们描述了现有的颗粒提取方法及其在使用多种检测技术分析弹性密封件组件中的适用性。建立了最佳的样品制备和分析技术,以评估弹性密封件组件中的亚微米颗粒和 SbVP 负载。此外,还评估了硅化瓶塞和聚山梨酯 80 相互作用对最终药物产品中 SbVPs 程度的影响。